Dimensional Fund Advisors LP Acquires New Position in Atyr PHARMA INC (NASDAQ:ATYR)

Dimensional Fund Advisors LP bought a new position in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 243,369 shares of the company's stock, valued at approximately $881,000. Dimensional Fund Advisors LP owned approximately 0.29% of Atyr PHARMA at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its position in shares of Atyr PHARMA by 467.8% during the 4th quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company's stock valued at $646,000 after acquiring an additional 147,092 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in shares of Atyr PHARMA during the 4th quarter valued at $144,000. Raymond James Financial Inc. bought a new stake in shares of Atyr PHARMA during the 4th quarter worth $39,000. Wells Fargo & Company MN purchased a new position in shares of Atyr PHARMA in the 4th quarter worth about $383,000. Finally, American Century Companies Inc. purchased a new stake in Atyr PHARMA in the fourth quarter worth approximately $319,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ATYR has been the topic of several recent research reports. Leerink Partnrs raised shares of Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Atyr PHARMA in a research report on Monday. Finally, Leerink Partners began coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $18.60.

Atyr PHARMA Price Performance

NASDAQ:ATYR opened at $3.75 on Thursday. Atyr PHARMA INC has a 52 week low of $1.42 and a 52 week high of $4.66. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The business's 50-day simple moving average is $3.25 and its two-hundred day simple moving average is $3.41. The stock has a market cap of $333.77 million, a PE ratio of -3.99 and a beta of 0.79.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.02. As a group, analysts forecast that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.